DHEA-S Drug Interactions: Which Medications Distort Your Test Results

What DHEA-S Actually Measures

DHEA-S is the sulfated storage form of dehydroepiandrosterone, secreted almost entirely by the adrenal zona reticularis. Because its half-life runs 7 to 10 hours compared with the 15 to 30 minutes for free DHEA, the sulfated form provides a stable snapshot of adrenal androgen activity without significant diurnal fluctuation. Labrie F et al., J Steroid Biochem Mol Biol, 2010 established the zona reticularis as the near-exclusive source, which is why the test tracks adrenal rather than gonadal function.

Why the Number Matters Clinically

Elevated DHEA-S drives a diagnostic workup for adrenal androgen-secreting tumors, non-classic congenital adrenal hyperplasia (NCCAH), and polycystic ovary syndrome. The Endocrine Society's 2018 PCOS guideline recommends measuring DHEA-S specifically to differentiate ovarian from adrenal androgen sources when total testosterone exceeds 200 ng/dL. Azziz R et al., J Clin Endocrinol Metab, 2018

Low DHEA-S, below 80 mcg/dL in adults under 50, may indicate adrenal insufficiency, hypothalamic-pituitary suppression, or simply accelerated adrenal aging. The AACE 2022 adrenal insufficiency guidelines list DHEA-S as a useful corroborating marker alongside an 8 AM cortisol. Bancos I et al., Endocr Pract, 2022

Assay Methodology and Its Limits

Most clinical labs use chemiluminescent immunoassay (CLIA) platforms. Cross-reactivity with DHEA, androstenedione, and some drug metabolites is a known limitation. Mass spectrometry-based assays reduce this interference but remain less common outside academic centers. Handelsman DJ, Wartofsky L, J Clin Endocrinol Metab, 2013 documented immunoassay-to-LC-MS/MS discordance of up to 15% in samples from patients on valproate, reinforcing that the assay platform matters when drug interactions are suspected.

Drugs That Suppress DHEA-S

Several drug classes lower the measured DHEA-S value either by reducing adrenal androgen synthesis directly, by increasing hepatic sulfation and clearance, or by suppressing the hypothalamic-pituitary-adrenal (HPA) axis upstream.

Glucocorticoids

Exogenous glucocorticoids are the single most common pharmacologic cause of low DHEA-S. Even moderate doses of prednisone (10 mg/day for 4 weeks) suppress ACTH secretion, which in turn reduces zona reticularis stimulation. Finkielman JD et al., Mayo Clin Proc, 2003 showed DHEA-S fell below the age-adjusted reference interval in 78% of patients on chronic prednisone therapy.

Inhaled fluticasone at doses above 500 mcg/day has produced measurable HPA suppression in some studies, though the DHEA-S effect is smaller and inconsistent. Todd GR et al., Arch Dis Child, 2002 found significant cortisol and DHEA-S suppression with high-dose inhaled steroids in children, a finding that transfers to adults on high-dose maintenance therapy.

Topical corticosteroids over large surface areas can produce the same effect. If a patient presents with low DHEA-S and takes any glucocorticoid by any route, the drug is the most likely explanation.

Oral Contraceptives and Estrogen-Containing Therapies

Combined oral contraceptives (COCs) lower DHEA-S by 20 to 40% through at least two mechanisms: direct suppression of LH (which carries a small adrenal trophic effect) and upregulation of hepatic steroid sulfotransferases that accelerate DHEA sulfation and excretion. Zimmerman Y et al., Eur J Contracept Reprod Health Care, 2014 analyzed 42 clinical trials and confirmed COC-induced reductions in DHEA-S averaging 30%.

Transdermal estradiol, used in menopausal hormone therapy, causes a smaller and less consistent effect. Oral estradiol (not transdermal) has a stronger hepatic first-pass effect and more reliably lowers DHEA-S. Women on oral estrogen-containing HRT should have their DHEA-S interpreted with a 20 to 30% downward adjustment in mind.

Progestin-only pills and the levonorgestrel IUD have minimal documented effect on DHEA-S in most studies, though high-dose injectable progestins (depot medroxyprogesterone acetate) may modestly suppress adrenal androgens. Venkatesh SS et al., Contraception, 2020

Metformin and Insulin Sensitizers

Metformin lowers DHEA-S in women with PCOS and insulin resistance. The reduction averages 10 to 20% over 3 to 6 months of therapy. Bridger T et al., J Pediatr, 2006 demonstrated a 19% fall in DHEA-S in adolescent girls with PCOS after 6 months on 1,500 mg/day metformin, attributed to improved insulin signaling reducing adrenal androgen drive.

Thiazolidinediones (pioglitazone, rosiglitazone) may produce similar though less-studied effects via PPAR-gamma-mediated reduction in adrenal steroidogenesis. Ordering a DHEA-S panel without noting concurrent metformin use in a PCOS workup can produce a falsely reassuring result.

Anticonvulsants: Carbamazepine and Phenytoin

Carbamazepine and phenytoin are potent inducers of CYP3A4 and hepatic sulfotransferases. Both drugs accelerate DHEA-S metabolism and lower circulating levels by 15 to 35%. Sveberg Roste L et al., Acta Neurol Scand, 2005 measured DHEA-S in women on carbamazepine versus valproate and found carbamazepine lowered DHEA-S by 28% relative to valproate-treated controls.

Oxcarbazepine, structurally related to carbamazepine, produces a similar though somewhat smaller effect. Patients on any enzyme-inducing anticonvulsant presenting for adrenal or androgen testing need explicit documentation of the drug and its duration.

Opioids

Chronic opioid therapy suppresses the HPA axis via mu-opioid receptor activity in the hypothalamus, reducing CRH and ACTH release. Abs R et al., J Clin Endocrinol Metab, 2000 found DHEA-S below the reference range in 47% of patients on long-term intrathecal opioids. Oral chronic opioid users showed similar though less severe suppression.

The clinical problem arises when a pain management patient is evaluated for fatigue or low libido. A low DHEA-S may be entirely opioid-driven rather than primary adrenal disease.

Drugs That Raise DHEA-S

Fewer drugs raise DHEA-S, but the ones that do can mimic adrenal tumor physiology if the treating clinician is unaware.

Exogenous DHEA Supplements

Over-the-counter DHEA supplements (typically 25 to 100 mg/day) are the most common cause of a pharmacologically elevated DHEA-S. A 50 mg oral DHEA dose can raise serum DHEA-S by 200 to 400 mcg/dL within 2 to 3 hours. Baulieu EE et al., Proc Natl Acad Sci USA, 2000 confirmed dose-dependent DHEA-S rises in the DHEAge study (N=280), with serum DHEA-S returning to near-baseline within 4 to 6 weeks of cessation.

Patients often do not volunteer supplement use. Direct questioning about OTC hormonal supplements is mandatory before ordering a DHEA-S panel.

Valproate

Valproate raises DHEA-S by inhibiting hepatic steroid sulfotransferases, reducing the sulfation and clearance of DHEA. Roste LS et al., Acta Neurol Scand, 2005 showed women on valproate had DHEA-S levels approximately 30% higher than age-matched controls, and significantly higher than carbamazepine-treated patients on the same seizure burden.

This is clinically meaningful in women with epilepsy evaluated for PCOS, as valproate independently elevates both DHEA-S and androstenedione, potentially generating a false positive adrenal androgen excess picture.

Certain Antipsychotics

Clozapine and olanzapine have been associated with elevated DHEA-S in several observational studies. The mechanism appears to involve reduced hepatic clearance and possible direct adrenal stimulation via prolactin-mediated pathways. Ritsner M et al., Neuropsychopharmacology, 2004 measured DHEA-S in 60 patients on atypical antipsychotics and found clozapine-treated patients had DHEA-S levels 40% above drug-naive controls.

Haloperidol and typical antipsychotics appear to have less effect on DHEA-S, though data are sparse.

Danazol

Danazol, a synthetic androgen used for endometriosis and hereditary angioedema, cross-reacts directly with DHEA-S immunoassay antibodies and also raises DHEA-S biologically by suppressing sex hormone-binding globulin and shifting androgen metabolism. The result is a markedly elevated DHEA-S that reflects the drug itself rather than adrenal output. Fedele L et al., Fertil Steril, 1990 documented DHEA-S values exceeding 600 mcg/dL in women on danazol 600 mg/day regardless of adrenal status.

Mifepristone

Mifepristone (RU-486), used in Cushing's syndrome management, can paradoxically raise DHEA-S. By blocking glucocorticoid receptors, mifepristone removes negative feedback on the HPA axis, raising ACTH and consequently adrenal androgen output. Fleseriu M et al., J Clin Endocrinol Metab, 2012 reported mean DHEA-S increases of 60 to 80 mcg/dL in Cushing's patients on mifepristone, complicating biochemical monitoring.

Normal DHEA-S Ranges by Age and Sex

Reference ranges are age-stratified because DHEA-S peaks in the third decade and falls predictably thereafter. The values below are drawn from published Endocrine Society and AACE consensus data.

| Age Range | Female (mcg/dL) | Male (mcg/dL) | |---|---|---| | 18 to 29 | 65 to 380 | 280 to 640 | | 30 to 39 | 45 to 270 | 120 to 520 | | 40 to 49 | 32 to 240 | 95 to 530 | | 50 to 59 | 26 to 200 | 70 to 310 | | 60 to 69 | 13 to 130 | 42 to 290 | | 70+ | 10 to 90 | 28 to 175 |

Orentreich N et al., J Clin Endocrinol Metab, 1984 established the foundational age-decline curve for DHEA-S in 245 adults followed longitudinally, confirming the ~2% per year decline beginning after age 30. Labrie F et al., J Clin Endocrinol Metab, 1997 extended this to 2,931 subjects across five age decades.

Sex Differences in Reference Ranges

Males consistently run higher DHEA-S than age-matched females throughout adulthood, reflecting greater zona reticularis mass. Post-menopausal women who are not on glucocorticoids or COCs often show DHEA-S levels in the 30 to 90 mcg/dL range, which is physiologically appropriate rather than pathologically low. Treating a post-menopausal DHEA-S of 45 mcg/dL as "deficiency" in the absence of clinical symptoms has no guideline support. Arlt W, Endocrinol Metab Clin North Am, 2004

Pediatric Values

In pre-pubertal children, DHEA-S below 20 mcg/dL is normal. Adrenarche, the developmental activation of the zona reticularis, raises DHEA-S from age 6 to 8 onward. DHEA-S above 130 mcg/dL before age 8 in girls or age 9 in boys raises concern for premature adrenarche and warrants referral. Ibáñez L et al., Horm Res, 2000

How to Raise DHEA-S (When Clinically Indicated)

No current major guideline endorses routine DHEA-S replacement in aging adults without documented adrenal insufficiency. The Endocrine Society's 2019 testosterone therapy guideline explicitly does not recommend DHEA supplementation for age-related decline in the absence of hypoadrenalism. Bhasin S et al., J Clin Endocrinol Metab, 2019

Adrenal Insufficiency: The One Evidence-Based Indication

In women with primary or secondary adrenal insufficiency on standard cortisol and fludrocortisone replacement, the Endocrine Society 2016 adrenal insufficiency guideline suggests (weak recommendation, low-quality evidence) a 6-month trial of oral DHEA 25 to 50 mg/day, targeting mid-normal female DHEA-S ranges. Bornstein SR et al., J Clin Endocrinol Metab, 2016 The same guideline does not extend this recommendation to men, as testicular androgen production compensates for the adrenal deficit.

The DHEA trial in adrenal insufficiency reported modest improvements in fatigue and sexual well-being scores in the Arlt et al. Randomized controlled trial (N=24, crossover design), with DHEA-S rising from a mean of 28 mcg/dL to 182 mcg/dL on 50 mg/day. Arlt W et al., N Engl J Med, 1999

Removing the Suppressing Drug

The most effective way to raise a pharmacologically low DHEA-S is removing or tapering the offending agent. After stopping COCs, DHEA-S typically returns to baseline within 4 to 6 weeks. After stopping prednisone in a patient without underlying HPA axis disease, recovery may take 3 to 12 months depending on cumulative dose and duration. Oelkers W, N Engl J Med, 1996

How to Lower DHEA-S (When Elevated)

Glucocorticoid Therapy for Adrenal Androgen Excess

In NCCAH (21-hydroxylase deficiency), low-dose glucocorticoid therapy (hydrocortisone 10 to 15 mg/day or dexamethasone 0.25 mg nightly) suppresses ACTH drive and lowers DHEA-S to target ranges. The Endocrine Society 2018 CAH guideline targets DHEA-S at the upper third of the age-sex reference range during treatment. Speiser PW et al., J Clin Endocrinol Metab, 2018

Over-suppression with dexamethasone is a known risk. DHEA-S should be checked every 6 months during dose titration to avoid iatrogenic adrenal suppression.

Oral Contraceptives in PCOS and Adrenal Androgen Excess

COCs lower DHEA-S 20 to 40% and are used clinically in PCOS patients with adrenal-predominant androgen excess. The reduction is not sufficient to treat adrenal tumors, but for functional adrenal hyperandrogenism (FAH), a combined OCP is a reasonable first-line option alongside lifestyle modification. Rosenfield RL, Ehrmann DA, Endocr Rev, 2016

Treating Insulin Resistance

Reducing hyperinsulinemia through weight loss, metformin, or GLP-1 receptor agonists reliably lowers DHEA-S in PCOS patients with insulin resistance. STEP-1 (N=1,961) demonstrated 14.9% mean weight loss with semaglutide 2.4 mg at 68 weeks versus 2.4% with placebo. Wilding JPH et al., N Engl J Med, 2021 Downstream DHEA-S reduction from weight loss-related insulin sensitization has been documented in multiple PCOS weight-loss trials, including a 12-week trial by Hoeger et al. (N=48) showing 22% DHEA-S reduction with structured caloric restriction. Hoeger KM et al., J Clin Endocrinol Metab, 2004

Interpreting DHEA-S When the Patient Is on Multiple Drugs

A systematic interpretation framework reduces clinical error when polypharmacy is present. Consider this five-step approach before ordering or interpreting DHEA-S in any patient on two or more chronic medications:

Step 1. List every drug and supplement. Ask specifically about OTC hormonal products, inhaled steroids, topical steroids, and recreational substances.

Step 2. Classify each drug. Assign each to one of three categories: known suppressor, known elevator, or no known effect. Use the table in the next section.

Step 3. Estimate the net directional bias. If the patient is on both an OCP (suppressor) and valproate (elevator), the competing effects may partially cancel, making the result difficult to interpret without a washout.

Step 4. Decide whether a washout is feasible. For stable patients, a 6-week washout from the offending agent before retesting gives a cleaner result. For patients on glucocorticoids for life-threatening disease, washout is not an option. Document this limitation explicitly in the chart.

Step 5. Use a second marker. When drug interference is suspected and washout is not possible, add 17-hydroxyprogesterone (for NCCAH), androstenedione, or a full adrenal stimulation test to triangulate. Speiser PW et al., J Clin Endocrinol Metab, 2018

Drug Effect Summary Table

| Drug / Drug Class | Direction | Mechanism | Magnitude | Washout to Clear | |---|---|---|---|---| | Prednisone / any systemic GC | Decrease | HPA suppression | 30 to 80% | 3 to 12 months | | Inhaled fluticasone >500 mcg/day | Decrease | Partial HPA suppression | 10 to 25% | 4 to 8 weeks | | Combined oral contraceptives | Decrease | Hepatic sulfotransferase induction | 20 to 40% | 4 to 6 weeks | | Oral estradiol (HRT) | Decrease | Hepatic first-pass effect | 15 to 25% | 4 to 6 weeks | | Metformin | Decrease | Reduced insulin-mediated adrenal drive | 10 to 20% | 4 to 6 weeks | | Carbamazepine | Decrease | CYP3A4 / sulfotransferase induction | 20 to 35% | 4 to 8 weeks | | Phenytoin | Decrease | CYP3A4 induction | 15 to 30% | 4 to 6 weeks | | Chronic opioids | Decrease | HPA axis suppression via mu receptor | 20 to 50% | 4 to 12 weeks | | Exogenous DHEA supplement | Increase | Direct substrate loading | 200 to 400 mcg/dL absolute | 4 to 6 weeks | | Valproate | Increase | Sulfotransferase inhibition | 20 to 35% | 4 to 6 weeks | | Clozapine / olanzapine | Increase | Reduced hepatic clearance | 30 to 45% | 6 to 8 weeks | | Danazol | Increase | Direct cross-reactivity + androgenic effect | Variable, may exceed 600 mcg/dL | 6 to 8 weeks | | Mifepristone | Increase | Glucocorticoid receptor blockade, raised ACTH | 60 to 80 mcg/dL absolute | 4 to 6 weeks |

When to Retest After Drug Discontinuation

The Endocrine Society does not publish a specific DHEA-S retest interval after drug discontinuation, but physiologic and pharmacokinetic data support the following estimates:

After stopping COCs, DHEA-S returns to baseline in 4 to 6 weeks for most women, as shown in a 12-week prospective study by van der Vange et al. van der Vange N et al., Contraception, 1991 After stopping systemic glucocorticoids in a patient without underlying adrenal disease, the HPA axis typically recovers over 3 to 12 months depending on cumulative steroid dose; retesting DHEA-S before 3 months risks a persistently suppressed reading that reflects HPA recovery lag rather than pathology. Oelkers W, N Engl J Med, 1996

After stopping exogenous DHEA supplements, circulating DHEA-S returns to pretreatment levels within 4 to 6 weeks. Baulieu et al. Confirmed this in the DHEAge trial. Baulieu EE et al., Proc Natl Acad Sci USA, 2000

A retest at 6 weeks post-washout is appropriate for most non-glucocorticoid offenders. For patients coming off long-term systemic corticosteroids, waiting 3 months before retesting DHEA-S is the more defensible clinical choice.